SCHEDULE: Soleus Capital Discloses 1% Stake in STAAR Surgical

Sentiment:

Beneficial Ownership Disclosure


Soleus Capital Master Fund and related entities have reported a 1.0% beneficial ownership stake in STAAR Surgical Company, totaling 500,000 shares.

Summary

  • Soleus Capital Master Fund, L.P. and its affiliated entities (Soleus Capital, LLC, Soleus Capital Group, LLC, Soleus Capital Management, L.P., Soleus GP, LLC, and Guy Levy) have reported beneficial ownership of STAAR Surgical Company common stock.
  • The aggregate amount beneficially owned by these reporting persons is 500,000 shares.
  • This represents 1.0% of STAAR Surgical Company's common stock outstanding.
  • The percentage is calculated based on 49,741,953 shares outstanding as of October 31, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q.
  • The reporting persons have shared voting power and shared dispositive power over all 500,000 shares.
  • The shares were not acquired for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of beneficial ownership by an institutional investor, indicating a 1.0% stake in STAAR Surgical Company. It does not contain operational or financial performance data that would typically influence sentiment.

Positives

  • An institutional investor, Soleus Capital Master Fund, L.P., has disclosed a 1.0% stake in STAAR Surgical Company, indicating an investment interest.

Risks

  • The reporting persons disclaim beneficial ownership of the shares for any purpose other than determining their obligations under Section 13(d) of the Securities Exchange Act of 1934, as amended.

Future Outlook

NA

Industry Context

This filing indicates an institutional investor's position in a medical device company specializing in ophthalmology. It does not provide broader industry trends or specific competitive analysis.

Stakeholder Impact

  • Shareholders: The disclosure of a 1.0% stake by an institutional investor might be viewed as a minor vote of confidence, but it is not a controlling or activist stake.

Key Dates

DateDescription
09/30/2025Date of event which requires filing of this statement.
10/31/2025Date as of which 49,741,953 shares of common stock were outstanding, as reported on the Issuer's Form 10-Q.
11/05/2025Date STAAR Surgical Company's Quarterly Report on Form 10-Q for the fiscal quarter ended September 26, 2025, was filed.
11/07/2025Date of signature for the Schedule 13G filing.

Keywords

STAAR Surgical Company, Soleus Capital, Schedule 13G, beneficial ownership, common stock, institutional investment, equity stake, SEC filing, ophthalmology, medical devices

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.